Table 3.
Results of the linear mixed model of the effect of CGM on HbA1c change.
| CGM non-users (n = 310) (β, 95% CI) |
CGM users (n = 155) (β, 95% CI) |
P-value | |
|---|---|---|---|
| Overall average reduction of HbA1c (%) each three months | −0.01 (−0.04, 0.02) | −0.12 (−0.16, −0.08) | <0.001 |
| Average difference of HbA1c (%) each three months | |||
| Model 1 | 0 (reference) | −0.11 (−0.16, −0.07) | <0.001 |
| Model 2 | 0 (reference) | −0.11 (−0.16, −0.06) | <0.001 |
| Model 3 | 0 (reference) | −0.11 (−0.16, −0.06) | <0.001 |
Model 1 is the unadjusted model; model 2 is adjusted for age, sex, BMI, and baseline HbA1c; model 3 is further adjusted for eGFR, total cholesterol, HDL, LDL, TG, duration of diabetes, total daily dose of insulin, and insulin regimen.
BMI, body mass index; CGM, continuous glucose monitoring; CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride.